Skip to main content

Table 2 Selected baseline patient characteristics for patients with a baseline and ≥1 follow-up PET scan

From: 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer

Characteristic

nab-Paclitaxel Dosea

100 mg/m2

(n = 13)

125 mg/m2

(n = 38)

All dose levels

(n = 52)

Age, median (range), years

57.0 (30–79)

61.0 (28–76)

61.0 (28–79)

Male sex, n (%)

7 (54)

17 (45)

24 (46)

ECOG PS, n (%)

 0

6 (46)

21 (55)

28 (54)

 1

7 (54)

17 (45)

24 (46)

CA 19–9 at baseline, median (range), units/mL

n = 12

1220.1 (16.8–180,062.0)

n = 37

880.8 (1.1–96,990.0)

n = 50

1062.6 (1.1–180,062.0)

  1. a1 patient received nab-paclitaxel 150 mg/m2 and their baseline characteristics are included in the “All dose levels” column
  2. CA 19–9 carbohydrate antigen 19–9, ECOG PS Eastern Cooperative Oncology Group performance status, PET positron emission tomography